1.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

2.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

3.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

4.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

5.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

6.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

7.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

1.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

2.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

3.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

4.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

5.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

6.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

7.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

8.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

9.

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

1.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

2.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

3.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

4.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

5.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

6.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

7.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

8.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

9.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

1.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

2.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

3.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

4.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

5.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

6.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

7.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

8.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

9.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

1.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

2.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

3.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

4.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

5.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

6.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

7.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

8.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

9.

Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients.

1.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

2.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

3.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

4.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

5.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

6.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

7.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

8.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

9.

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

1.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

2.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

3.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

4.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

5.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

6.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

7.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

8.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

9.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

1.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

2.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

3.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

4.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

5.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

6.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

7.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

8.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

9.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

1.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

2.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

3.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

4.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

5.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

6.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

7.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

8.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

9.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

1.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

2.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

3.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

4.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

5.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

6.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

7.

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.